Northwest Bio's long-awaited glioblastoma vaccine data see stock roller coaster

Northwest Bio unveiled interim phase 3 data showing its dendritic cell vaccine improved survival rates in patients with newly diagnosed glioblastoma, in some cases even doubling survival. Northwest's stock shot up 35% on the news, but its Tuesday high of $0.31 still puts the biotech in penny-stock territory, and promptly fell about 10% after-hours.